SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions

Human Pathology

Volumn 43, Issue 5, 2012, Pages 669-674

  Bock, Annika J ^a,b   Nymoen, Dag Andre ^a   Brenne, Kjersti ^a   Kærn, Janne ^a   Davidson, Ben ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Chemotherapy; Ovarian carcinoma; Quantitative PCR; SCARA3; Survival

Indexed keywords

CARBOPLATIN; EPIRUBICIN; GEMCITABINE; MESSENGER RNA; PACLITAXEL; PROTEIN SCARA3; SCAVENGER RECEPTOR A; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; MONOTHERAPY; OVARY CARCINOMA; PERITONEUM EXUDATE; PLEURA EFFUSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS A;

EID: 84859902967     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.06.003     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
3. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9-12. (Pubitemid 27026949)
4. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278-87. (Pubitemid 29118182)
5. Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767-75. (Pubitemid 29109304)
6. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol 2004;31:246-54. (Pubitemid 39314820)
7. Davidson B, Stavnes HT, Holth A, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 2011;15:535-44.
8. Han HJ, Tokino T, Nakamura Y. CSR, a scavenger receptor-like protein with a protective role against cellular damage caused by UV irradiation and oxidative stress. Hum Mol Genet 1998;7:1039-46. (Pubitemid 28256598)
9. Yu G, Tseng GC, Yu YP, et al. CSR1 suppresses tumor growth and metastasis of prostate cancer. Am J Pathol 2006;168:597-607. (Pubitemid 43271157)
10. Zhu ZH, Yu YP, Shi YK, Nelson JB, Luo JH. CSR1 induces cell death through inactivation of CPSF3. Oncogene 2009;28:41-51.
11. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999;435:43-9. (Pubitemid 29346741)
12. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12. (Pubitemid 33022056)
13. Yuan Y, Nymoen DA, Stavnes HT, et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 2009;33:1673-82.
14. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474-86. (Pubitemid 38072587)
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. (Pubitemid 11167383)
16. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006;24:1115-22. (Pubitemid 44359723)
17. Yuan Y, Nymoen DA, Dong HP, et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. HUM PATHOL 2009;40:1453-60.
18. Bustin SA, Benes V, Nolan T, Pfaffl MW. Quantitative real-time RT-PCR - a perspective. J Mol Endocrinol 2005;34:597-601. (Pubitemid 40903586)
19. Davidson B. Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog 2007;13:189-227. (Pubitemid 351239093)
20. Davidson B, Reich R, Trope' CG, Wang TL, Shih IeM. New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol 2010;25:1591-609.
21. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003;4:117.